TEVA PHARMACEUTICAL INDUSTRIES LTD Q3 FY25 Results
TEVAQ3 FY25 ResultsAnnounced Nov 5, 2025, 07:00 AM| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 4.5K | 7.3% | 3.4% |
| Total Income | 4.5K | 7.3% | 3.4% |
| Expenditure | 3.6K | 3.3% | 17.9% |
| PBT | 646.00 | 218.2% | 299.4% |
| Net Profit | 433.00 | 53.5% | 199.1% |
| OPM | 19.69% | 8.79pp | 20.87pp |
| NPM | 9.66% | 2.91pp | 19.75pp |
| EPS | 0.38 | 52.0% | 197.4% |
Teva Reports Q3 2025 Revenue of $4.5 Billion, Up 3% Y-o-Y
04 May 2026 · 4 May, 7:54 am
Summary
Teva Pharmaceutical Industries Ltd. reported a 3% increase in revenue to $4.5 billion for Q3 2025. The growth was primarily driven by key innovative brands, which saw a 33% increase in revenue. AUSTEDO, AJOVY, and UZEDY continue to perform strongly, leading to an increased revenue outlook for AUSTEDO. The company is on track to achieve its non-GAAP operating profit margin target of 30% by 2027.
Key Highlights
- 1
Teva's Q3 2025 revenues reached $4.5 billion, reflecting a 3% increase year-over-year in U.S. dollars.
- 2
Key innovative brands drove growth, with revenues increasing by 33% year-over-year in local currency to $830 million.
- 3
AUSTEDO's global revenues in Q3 2025 were $618 million, marking a 38% increase in local currency year-over-year.
- 4
The company is increasing the AUSTEDO 2025 revenue outlook by $50 million - $100 million to a new range of $2,050 million - $2,150 million.
- 5
Global revenues for AJOVY reached $168 million, representing a 19% increase in local currency year-over-year.
- 6
UZEDY generated revenues of $43 million, showing a 24% increase year-over-year.
- 7
Teva reaffirms its 2025 revenue outlook for AJOVY at $630 million - $640 million and for UZEDY at $190 million - $200 million.
Management Comments
Richard Francis
Our innovative portfolio driving the 11th consecutive quarter of growth in the third quarter reflects the accelerating momentum of our transformation and the strength of our innovation-led Pivot to Growth strategy. Our key growth drivers—particularly our innovative medicines—delivered a 33% increase in local currency, underscoring their impact on both patient outcomes and our financial performance. As we continue executing our strategy, we remain firmly on track to reach our 30% non-GAAP operating profit margin by 2027 and ~$700 million of net savings target. Following the conclusion of the IRA pricing negotiations, we are reiterating our strong confidence in our AUSTEDO 2027 target. Our differentiated innovative portfolio is now a defining strength for Teva as we transform into a leading innovative biopharma, while our world-class generics business continues to provide a resilient foundation. With our talented team and unwavering commitment to patients, we are confident about Teva’s future and our ability to deliver enduring value to all our stakeholders.”
Informational and educational content only. Not investment advice.